| Literature DB >> 27622054 |
Ilona Kryczek1, Lin Wang2, Ke Wu3, Wei Li3, Ende Zhao3, Tracy Cui4, Shuang Wei4, Yan Liu4, Yin Wang4, Linda Vatan4, Wojciech Szeliga4, Joel K Greenson5, Jacek Roliński6, Witold Zgodzinski7, Emina Huang8, Kaixiong Tao2, Guobin Wang2, Weiping Zou4.
Abstract
Foxp3(+)CD4(+) regulatory T (Treg) cells are thought to express negligible levels of effector cytokines, and inhibit immune responses and inflammation. Here, we have identified a population of IL-8(+)Foxp3(+)CD4(+) T cells in human peripheral blood, which is selectively increased in the microenvironments of ulcerative colitis and colon carcinoma. Phenotypically, this population is minimally overlapping with IL-17(+)Foxp3(+)CD4(+) T cells, and is different from IL-8(-)Foxp3(+)CD4(+) T cells in the same microenvironment. 40-60% of IL-8(+)Foxp3(+)CD4(+) T cells exhibit naive phenotype and express CD127, whereas IL-8(-)Foxp3(+)CD4(+) cells are basically memory T cells and express minimal CD127. The levels of CXCR5 expression are higher in IL-8(+)Foxp3(+) cells than in IL-8(-)Foxp3(+) cells. IL-2 and TGFβ induce IL-8(+)Foxp3(+) T cells. Exogenous Foxp3 expression promotes IL-8(+)Foxp3(+) T cells and inhibits effector cytokine IFNγ and IL-2 expression. Furthermore, Foxp3 binds to IL-8 proximal promoter and increases its activity. Functionally, IL-8(+)Foxp3(+) T cells inhibit T cell proliferation and effector cytokine production, but stimulate inflammatory cytokine production in the colon tissues, and promote neutrophil trafficking through IL-8. Thus, IL-8(+)Foxp3(+) cells may be an "inflammatory" Treg subset, and possess inflammatory and immunosuppressive dual biological activities. Given their dual roles and localization, these cells may be in a unique position to support tumor initiation and development in human chronic inflammatory environment.Entities:
Keywords: Colon carcinoma; IL-17; IL-8; Regulatory T cell; Th17; neutrophil; tumor immunity; ulcerative colitis
Year: 2016 PMID: 27622054 PMCID: PMC5007964 DOI: 10.1080/2162402X.2015.1105430
Source DB: PubMed Journal: Oncoimmunology ISSN: 2162-4011 Impact factor: 8.110